Schering-Plough to Cut 5,500 Jobs
In what CEO and Chairman Fred Hassan is calling “tough actions that are needed to respond to a tough situation,” Schering-Plough (Kenilworth, NJ) has announced plans to eliminate 5,500 jobs (10% of its workforce).
In what CEO and Chairman Fred Hassan is calling “tough actions that are needed to respond to a tough situation,” Schering-Plough (Kenilworth, NJ) has announced plans to eliminate 5,500 jobs (10% of its workforce). Their plan will reduce costs by $1.5 billion by 2012.
The announcement comes after physicians from the American College of Cardiology presented their findings on March 30 regarding cholesterol drugs Zetia and Vytorin, a major source of revenue for Schering. According to the panel, Vytorin, a combination of Zetia and Zocor, is no more effective than Zocor alone, which is available as a cheaper generic, at slowing the progression of heart disease. Zetia and Vytorin are jointly marketed by Schering-Plough and Merck & Co. (Whitehouse Station, NJ).
The problems with Vytorin began in January when Schering-Plough and Merck released the findings from their ENHANCE trial, which found that while Vytorin reduced LDL cholesterol, it had little effect on arterial plaque buildup.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
